
---
title: Anti-TB Drugs Cheat Sheet
markmap:
  colorFreezeLevel: 6
---

## Anti-TB Drugs (INICET High-Yield)

- ### Classification & Key Drugs
  - **First-Line** (RIPE + S)
    - **Rifampicin (R)**
      - MoA: Inhibits DNA-dependent RNA Polymerase
      - SE: Hepatitis, Orange secretions, Enzyme Inducer, Flu-like syndrome, Thrombocytopenia
    - **Isoniazid (H)**
      - MoA: Inhibits Mycolic Acid Synthesis (KatG activation)
      - SE: Peripheral Neuropathy (Give Pyridoxine B6), Hepatitis, Drug Interactions (CYP Inhibitor)
    - **Pyrazinamide (Z)**
      - MoA: Active in acidic pH (Lysosomal), disrupts cell membrane/energy metabolism
      - SE: Hyperuricemia (Gouty Arthritis), Hepatitis, Photosensitivity
    - **Ethambutol (E)**
      - MoA: Inhibits Arabinosyl Transferase
      - SE: Optic Neuritis (Red-green color blindness), Peripheral Neuropathy
    - **Streptomycin (S)** - (Injectable, less used for DS-TB now)
      - MoA: 30S Ribosomal subunit
      - SE: Ototoxicity (Vestibular > Auditory), Nephrotoxicity, Teratogenic
  - **Second-Line Oral**
    - Fluoroquinolones (Moxi, Levo)
      - MoA: DNA Gyrase/Topoisomerase IV
      - SE: QT prolongation, Tendon rupture, CNS effects
    - Ethionamide/Prothionamide
      - SE: GI upset, Neuropsychiatric, Hypothyroidism
    - Cycloserine
      - SE: Neuropsychiatric (Psychosis, Seizures) - **Buzzword: C-S-C (Cycloserine-Serine-CNS)**
    - p-Aminosalicylic Acid (PAS)
      - SE: GI upset, Hypothyroidism, Drug interactions (INH absorption)
    - Linezolid
      - MoA: Inhibits 50S Ribosomal subunit
      - SE: Myelosuppression (Thrombocytopenia), Peripheral & Optic Neuropathy, Lactic Acidosis
    - Clofazimine
      - SE: Skin discoloration (Pink/Brownish), GI upset, QT prolongation
  - **Second-Line Injectable (Older)** - Less used due to toxicity/resistance
    - Amikacin, Kanamycin, Capreomycin (Ototoxicity, Nephrotoxicity)
  - **Newer Drugs (Key for MDR/XDR)**
    - **Bedaquiline (Bdq)**
      - MoA: Inhibits ATP Synthase
      - SE: QT Prolongation, Hepatotoxicity - **Buzzword: Bedaquiline-QT**
    - **Delamanid (Dlm)**
      - MoA: Inhibits Mycolic Acid Synthesis
      - SE: QT Prolongation, Peripheral Neuropathy
    - **Pretomanid (Pa)**
      - Used in combinations (BPaL/BPaLM)
      - SE: Peripheral Neuropathy, Myelosuppression, Hepatotoxicity
- ### Key Side Effects Summary (RIPE Mnemonic + others)
  - **R** - **R**ifampicin: **R**ed/Orange, Hepatitis, Enzyme induce**R**
  - **I** - **I**soniazid: Neuropathy (requires B6), Hepatitis
  - **P** - **P**yrazinamide: Hyperuricemia (Gout), Hepatitis
  - **E** - **E**thambutol: **E**ye (Optic neuritis - **E** count is 4 letters like 4th drug in RIPE)
  - **S** - **S**treptomycin: **S**ixth cranial nerve (Ototoxicity), Kidney
  - Fluoroquinolones: QT, Tendons
  - Cycloserine: CNS
  - Linezolid: Myelosuppression, Neuropathy
  - Bedaquiline/Delamanid: QT Prolongation
- ### Drug Resistance
  - RIF Resistance: rpoB gene mutation
  - INH Resistance: katG, inhA mutations
  - MDR-TB: Resistant to INH + RIF
  - XDR-TB: MDR-TB + resistance to Fluoroquinolone + â‰¥1 injectable (older)
  - Pre-XDR: MDR-TB + resistance to FQ *OR* injectable (older)
- ### Regimens (Simplified)
  - DS-TB: 6 months (Intensive: 2HRZE; Continuation: 4HR)
  - MDR-TB: Longer regimens, often including Newer Drugs, Linezolid, Clofazimine, FQ. Shorter regimens are now preferred.
  - **Buzzword Regimen:** **BPaL** (Bedaquiline, Pretomanid, Linezolid) - for specific DR-TB; **BPaLM** adds Moxifloxacin.
- ### INICET Buzzwords
  - **DOTS** (Directly Observed Treatment, Short-course)
  - **IPT** (Isoniazid Preventive Therapy)
  - **TPT** (TB Preventive Treatment - broader term)
  - **Latent TB Infection (LTBI)** vs Active TB Disease
  - **GeneXpert** (Rapid diagnosis & RIF resistance detection)
  - **LPA** (Line Probe Assay - Rapid DST)
  - **DST** (Drug Susceptibility Testing)
  - **Universal DST**
  - **Categorization** (Old system: Cat I, II, IV) - less used now with U-DST
  - **Paradoxical Reaction** (IRIS - Immune Reconstitution Inflammatory Syndrome in HIV)
  - **Management of Side Effects** (e.g., B6 for INH neuropathy)
  - **Drug-Induced Hepatitis** (Stop all drugs, reintroduce sequentially)
